Abstract | BACKGROUND: A number of new drugs for tumor immunotherapy have been approved in the past few years. They work by activating T cells to combat tumors. METHODS: This review is based on publications on recently approved T-cell-activating drugs that were retrieved by a selective search in PubMed. RESULTS: CONCLUSION: T-cell-directed strategies have been established as a new pillar of treatment in medical oncology. As these drugs have frequent and severe adverse effects, therapeutic decision-making will have to take account not only of the predicted prolongation of survival, but also of the potential for an impaired quality of life while the patient is under treatment.
|
Authors | Sebastian Kobold, Peter Duewell, Max Schnurr, Marion Subklewe, Simon Rothenfusser, Stefan Endres |
Journal | Deutsches Arzteblatt international
(Dtsch Arztebl Int)
Vol. 112
Issue 48
Pg. 809-15
(Nov 27 2015)
ISSN: 1866-0452 [Electronic] Germany |
PMID | 26667979
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Antibodies, Monoclonal
- Ipilimumab
- Receptors, Antigen, T-Cell
|
Topics |
- Antibodies, Monoclonal
(administration & dosage, immunology)
- Evidence-Based Medicine
- Humans
- Immunotherapy
(methods)
- Ipilimumab
- Molecular Targeted Therapy
(methods)
- Neoplasms
(immunology, pathology, therapy)
- Receptors, Antigen, T-Cell
(antagonists & inhibitors, immunology)
- T-Lymphocytes
(drug effects, immunology)
- Treatment Outcome
|